Home
overview
Asthma is one of the most common chronic diseases worldwide and affects more than 130 million people. In the EU and the United States asthma is thought to affect 38 million people. Although the symptoms can be controlled there is no cure.

Despite the already high amount spent on asthma treatments, there is further potential owing to under-diagnosis and under treatment. Moreover better patient compliance would further increase the market size. Talks at this conference on diagnostics and drug delivery will address these issues.

This event will also provide delegates with an understanding of the current trends in the prevalence of asthma, and an overview of today’s therapies. This will cover conventional therapies together with improved versions, and drugs in the pipeline.

There will also be talks on patent expiry and its implications for life-cycle strategy for the patent-holding organization and opportunity for the generic company.

In addition this event will deal with the challenges of clinical trials with a focus on the significance of the paediatric rule in the USA for asthma drugs and possible regulatory changes in the EU.

This information will enable Pharma, Biotech, and Generic companies to plan R & D, clinical trials, and marketing strategies based on tomorrow’s market, current trends and the unmet clinical needs of today.

A unique opportunity to learn from industry experts including:
· Dr Joan Soriano, Director, World Epidemiology, GlaxoSmithKline
· Dr Paul Wright, Associate Director, Product Development, AstraZeneca
· Dr Daniela S Bundschuh, Senior Project Manager, ALTANA Pharma
· Stephen Lewington, Vice President, Respiratory Disease, Global Marketing & Medical, Aventis
· Dr Ivan Richards, Distinguished Scientist & Fellow, Pharmacia
· Dr Silvia Ragno, Head, Pharmacology, Lorantis
· Prof John Staniforth, Chief Scientific Officer, Vectura

“An excellent opportunity to grasp all angles of asthma therapy”
Attendee SMi’s Asthma Therapeutics Conference 2002

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Prof Fan Chung

Prof Fan Chung, Professor of Respiratory Medicine, Imperial College School of Medicine

9:10 KEYNOTE ADDRESS

Dr Joan Soriano

Dr Joan Soriano, Director, World Epidemiology, GlaxoSmithKline

  • Disease overview and burden
  • Causes of asthma
  • Existing therapies: drug groups, efficacy and safety
  • Future trends in disease treatment
  • 9:40 OVERVIEW OF THE ASTHMA MARKET

    Stephen Lewington

    Stephen Lewington, Vice President, Respiratory Disease, Global Marketing & Medical, Aventis

  • Disease trends and unmet needs
  • Patient attitudes to asthma therapy
  • New developments in asthma therapy
  • Barriers to entry in the asthma market
  • Strategic partnering
  • 10:20 THE SEARCH FOR ASTHMA THERAPEUTICS: A TORTUOUS ROAD

    Dr Ivan Richards

    Dr Ivan Richards, Distinguished Scientist & Fellow, Pharmacia

  • Where have we been?
  • Where did we go wrong?
  • What have we learned?
  • Where are we heading?
  • 11:00 Morning Coffee

    11:20 SMALL MOLECULE THERAPEUTIC APPROACHES TO ASTHMA AND OTHER RESPIRATORY DISEASES

    Dr David Stirling

    Dr David Stirling, Chief Scientific Officer, Executive Vice President, Research & Development, Celgene

  • Novel PDE4 inhibitors
  • Non-clinical studies
  • Clinical development
  • Novel JNK inhibitors
  • Non-clinical data
  • Other signalling targets
  • 12:00 Networking Lunch

    12:00 THE NEED FOR NEW THERAPY

    Prof Albrecht Bufe

    Prof Albrecht Bufe, Department Leader, Experimental Pneumology & Clinical Research Group – ‘Viral Infection and Chronic Pulmonary Disease’, Ruhr-University Bochum

  • Basic immunological aspects
  • Time of intervention
  • Anti-IgE
  • Cytokine and anti-cytokine treatment
  • Probiotics
  • Specific immunotherapy in asthma
  • 13:40 FROM STANDARD MEDICATIONS TO AN INDIVIDUALISED DRUG DELIVERY REGIME

    Dr Johannes-Christoph Stein

    Dr Johannes-Christoph Stein, International Business Development Manager, PARI

  • Therapy optimisation
  • Individual lung parameters
  • Therapeutic window
  • Children and babies as a special group
  • Reduction of side effects
  • New drug requirements
  • 14:20 REGULATORY T-CELLS AND THERAPEUTIC IMMUNE TOLERANCE

    Dr Silvia Ragno

    Dr Silvia Ragno, Head, Pharmacology, Lorantis

  • T-cells and asthma
  • Th1/Th2 and regulatory T-cells (Treg)
  • Treg modulation of airway pathology
  • Pathways for modulating Treg activity
  • Notch and Notch ligands
  • Manipulation of T cells by the Notch pathway
  • 15:00 JNK

    Dr Brydon Bennett

    Dr Brydon Bennett, Senior Scientist, Cellular & Molecular Pharmacology, Celgene

  • Effects of JNK inhibitors on animal models of airways hyperresponsiveness, lung inflammation and airways remodelling
  • Comparison between JNK inhibitors and corticosteroids
  • Progress in the development of CC401: the first JNK inhibitor to enter the clinic
  • 15:40 Afternoon Tea

    16:00 ORIGINS

    Prof John Staniforth

    Prof John Staniforth, Chief Scientific Officer, Vectura

  • What happens at the cell surface as well as within it?
  • Improving safety and tolerability
  • Achieving more efficacious delivery
  • Prolonging efficacious delivery
  • 16:40 IL-13 ANTAGONISM IN ASTHMA

    Dr Debra Donaldson

    Dr Debra Donaldson, Senior Scientist, Wyeth

  • Induction of airway hyperreactivity, mucus formation and airway remodelling in animal models of pulmonary disease
  • Recent human genetic data associating IL-13 and genes of the IL-13 signalling pathway to allergic diseases confirm the animal model predictions
  • Provision of a sound rationale for IL-13 antagonism as a therapeutic approach for the treatment of asthma
  • 17:20 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr Mark Parry-Billings

    Dr Mark Parry-Billings, Director, Research & Development, Innovata Biomed

    9:10 STERIODS: ARE THE REALLY SAFE?

    Prof Maria Belvisi

    Prof Maria Belvisi, Head, Respiratory Pharmacology Group, Imperial College School of Medicine, National Heart & Lung Institute

  • Inhaled corticosteroids provide effective treatment for asthma
  • Corticosteroid therapy represents a balance between safety and efficacy
  • All effects of corticosteroids, both beneficial and adverse, are mediated by the same receptor type
  • Limitations in current inhaled steroid include the incidence of side effects (including cortisol suppression, oral candidiasis, steroid-induced osteoporosis)
  • Several strategies have been adopted in the design of new steroids in order to limit the adverse side effects including optimising the pharmacokinetic profile of these compounds
  • 9:40 CPG OLIGONUCLEOTIDES

    Joel Kline

    Joel Kline, Associate Professor, Coley Pharmaceuticals

  • CpG ODNs: discovery and definition
  • Mechanism of action CpG DNA
  • Need for immunomodulatory therapy
  • Preclinical studies
  • Proof of concept in humans
  • Future directions
  • 10:20 PDE4 INHIBITORS

    Dr Daniela S Bundschuh

    Dr Daniela S Bundschuh, Senior Project Manager, ALTANA Pharma

  • PDE4 as an important target for the development of novel asthma therapies
  • Novel PDE4 inhibitors
  • Efficacy of selective PDE4 inhibitors, exemplified by Roflumilast
  • Overview on clinical data and new phase III data of Roflumilast
  • 11:00 Morning Coffee

    11:20 COMBINATION THERAPY IN ASTHMA

    Dr Mark Parry-Billings

    Dr Mark Parry-Billings, Director, Research & Development, Innovata Biomed

  • A brief and negative history
  • The market revolution
  • Compression marketing and where next?
  • The pharmacological and clinical stories
  • Successful delivery of combination products
  • 12:00 CLINICAL TRIALS IN ASTHMA

    Dr Alan Davies

    Dr Alan Davies, Therapeutic Director, Kendle

  • Appropriate outcome measures for clinical trials in asthma
  • The current gold standard result in clinical trials
  • Clinical trail endpoints in asthma
  • Quality of life and airway resistance
  • Gaining paediatric approval
  • Paediatric exclusivity
  • 12:40 Networking Lunch

    14:00 DIAGNOSIS OF ASTHMA

    Dr Kularisi Gunawardena

    Dr Kularisi Gunawardena, Director, Clinical Research, Chiltern International

  • The practical aspects of diagnosis
  • Diseases that may be confused with asthma
  • Asthma variants
  • Definition of asthma to be specified in the various types of protocols for clinical trials
  • 14:40 CHEMOKINE RECEPTOR ANTAGONISTS

    Prof Timothy J Williams

    Prof Timothy J Williams, National Asthma Campaign Professor, Head of Leukocyte Biology Section, Deputy Head of Biomedical Sciences Division, Imperial College

  • Chemokines are a large family of 50+ small chemotactic proteins that signal through approximately 20 different receptors on immune cells
  • Chemokines regulate the localisation of immune cells and hence control sensitisation to allergens
  • Chemokines are produced in the asthmatic lung and they control the influx of different types of inflammatory cell
  • Eotaxin is a chemokine produced in the asthmatic lung and it regulates the accumulation of eosinophils that are associated with tissue damage and lung dysfunction
  • Small molecule receptor (CCR3) antagonists have been produced that are being evaluated as potential therapy for asthma and allergy
  • 15:20 CHANGES IN DRUG DELIVERY

    Dr Paul Wright

    Dr Paul Wright, Associate Director, Product Development, AstraZeneca

  • Oral
  • Injection
  • Dry powder inhaler
  • Pressurised metered dose inhaler
  • Nebuliser systems
  • 16:00 Chairman's Closing Remarks followed by Afternoon Tea
    Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.